Detail akcie Cadrenal Inc Rg online

Business Summary: Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics to overcome the limitations of anticoagulation therapy. It has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Cadrenal Therapeutics Inc revenues was not reported. Net loss increased 58% to $10.2M. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase of 56% to $10.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$5.98 to -$5.27.